Related references
Note: Only part of the references are listed.Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study
Herve Tilly et al.
LANCET ONCOLOGY (2019)
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19
Maria Ormhoj et al.
CLINICAL CANCER RESEARCH (2019)
CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies
Hong Qin et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
Zachary J. Roberts et al.
LEUKEMIA & LYMPHOMA (2018)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Effects of cryopreservation on chimeric antigen receptor T cell functions
Hao Xu et al.
CRYOBIOLOGY (2018)
Continuous signaling of CD79b and CD19 is required for the fitness of Burkitt lymphoma B cells
Xiaocui He et al.
EMBO JOURNAL (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The promise of CAR T-cell therapy in aggressive B-cell lymphoma
Ranjit Nair et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena J. Orlando et al.
NATURE MEDICINE (2018)
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Irene Scarfo et al.
BLOOD (2018)
MYD88, CD79B, and CARD11 Gene Mutations in CD5-Positive Diffuse Large B-Cell Lymphoma
Toshifumi Takeuchi et al.
CANCER (2017)
New development in CAR-T cell therapy
Zhenguang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
Jeannette Fischer et al.
JOURNAL OF IMMUNOTHERAPY (2017)
Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis
Jochen Buechner et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
CD79B limits response of diffuse large B cell lymphoma to ibrutinib
Joo Hyun Kim et al.
LEUKEMIA & LYMPHOMA (2016)
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Elena Sotillo et al.
CANCER DISCOVERY (2015)
CD798 and MYD88 mutations in diffuse Large B-cell Lymphoma
Yuil Kim et al.
HUMAN PATHOLOGY (2014)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates
Bing Zheng et al.
MOLECULAR CANCER THERAPEUTICS (2009)
B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells
LG Ng et al.
JOURNAL OF IMMUNOLOGY (2004)
Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review
GA Kennedy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis
MS Cragg et al.
BLOOD (2002)
Share Paper
